1. Home
  2. BCRX vs FTRE Comparison

BCRX vs FTRE Comparison

Compare BCRX & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioCryst Pharmaceuticals Inc.

BCRX

BioCryst Pharmaceuticals Inc.

N/A

Current Price

$7.20

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

N/A

Current Price

$16.06

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCRX
FTRE
Founded
1986
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
BCRX
FTRE
Price
$7.20
$16.06
Analyst Decision
Strong Buy
Hold
Analyst Count
12
8
Target Price
$20.08
$12.07
AVG Volume (30 Days)
4.0M
1.4M
Earning Date
11-03-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$599,816,000.00
$2,759,900,000.00
Revenue This Year
$40.20
$3.17
Revenue Next Year
$7.71
$0.04
P/E Ratio
N/A
N/A
Revenue Growth
45.38
1.88
52 Week Low
$6.00
$3.97
52 Week High
$11.31
$20.86

Technical Indicators

Market Signals
Indicator
BCRX
FTRE
Relative Strength Index (RSI) 44.23 73.87
Support Level $7.23 $15.40
Resistance Level $7.92 $16.42
Average True Range (ATR) 0.35 1.02
MACD -0.02 0.18
Stochastic Oscillator 13.42 81.55

Price Performance

Historical Comparison
BCRX
FTRE

About BCRX BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: